ProPhase Labs (NASDAQ:PRPH) Posts Earnings Results, Beats Estimates By $0.06 EPS

ProPhase Labs (NASDAQ:PRPH) issued its quarterly earnings data on Tuesday. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.06, Zacks reports. ProPhase Labs had a negative net margin of 217.64% and a negative return on equity of 62.92%.

ProPhase Labs Price Performance

NASDAQ PRPH traded up $0.02 during trading hours on Tuesday, reaching $0.34. The company’s stock had a trading volume of 14,052,209 shares, compared to its average volume of 2,747,480. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.33 and a current ratio of 1.47. The stock has a market cap of $14.41 million, a PE ratio of -0.27 and a beta of -0.47. The company’s 50-day moving average is $0.34 and its two-hundred day moving average is $0.53. ProPhase Labs has a fifty-two week low of $0.22 and a fifty-two week high of $5.45.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on ProPhase Labs in a report on Tuesday, February 25th. They issued a “sell” rating on the stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.